Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors

被引：5
|
作者：
Duran, I.
Hotte, S.
Chen, E.
Hirte, H.
MacLean, M.
Turner, S.
Pond, G.
Wright, J.
Dancey, J.
Siul, L.
机构：
[1] Princess Margaret Hosp Phase II Consortium, Toronto, ON, Canada
[2] Natl Canc Inst, Bethesda, MD USA
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70555-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
550
引用
收藏
页码：167 / 167
页数：1
相关论文
共 50 条
  • [41] A phase i study of ixazomib and erlotinib in patients with advanced solid tumors
    Kato, Shumei
    Adashek, Jacob J.
    Subbiah, Vivek
    Fu, Siqing
    Sun, Mianen
    Nguyen, Ly
    Brown, Elsa J.
    Yap, Timothy A.
    Karp, Daniel D.
    Piha-Paul, Sarina A.
    Hong, David S.
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 99 - 105
  • [42] Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study
    Angela M Davies
    Cheryl Ho
    Paul J Hesketh
    Laurel A Beckett
    Primo N Lara
    Derick HM Lau
    David R Gandara
    Investigational New Drugs, 2007, 25 : 351 - 355
  • [43] A phase i study of ixazomib and erlotinib in patients with advanced solid tumors
    Shumei Kato
    Jacob J. Adashek
    Vivek Subbiah
    Siqing Fu
    Mianen Sun
    Ly Nguyen
    Elsa J. Brown
    Timothy A. Yap
    Daniel D. Karp
    Sarina A. Piha-Paul
    David S. Hong
    Investigational New Drugs, 2022, 40 : 99 - 105
  • [44] Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study
    Davies, Angela M.
    Ho, Cheryl
    Hesketh, Paul J.
    Beckett, Laurel A.
    Lara, Primo N., Jr.
    Lau, Derick H. M.
    Gandara, David R.
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (04) : 351 - 355
  • [45] Phase I study of paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
    Schultheis, B.
    Neumann, H.
    Roy, R.
    Kummer, G.
    Strumberg, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Phase I study with paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
    Schultheis, B.
    Neumann, H.
    Roy, R.
    Heuer, V
    Kummer, G.
    Strumberg, D.
    ONKOLOGIE, 2011, 34 : 110 - 110
  • [47] Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors
    Simonelli, Matteo
    Zucali, Paolo A.
    Lorenzi, Elena
    Rubino, Luca
    De Vincenzo, Fabio
    De Sanctis, Rita
    Perrino, Matteo
    Mancini, Luca
    Di Tommaso, Luca
    Rimassa, Lorenza
    Masci, Giovanna
    Zuradelli, Monica
    Suter, Matteo B.
    Bertossi, Monica
    Fattuzzo, Giuseppe
    Giordano, Laura
    Roncalli, Massimo G.
    Santoro, Armando
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (05) : 989 - 998
  • [48] A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors
    Haeseong Park
    Kerry Williams
    Nikolaos A. Trikalinos
    Sarah Larson
    Benjamin Tan
    Saiama Waqar
    Rama Suresh
    Daniel Morgensztern
    Brian A. Van Tine
    Ramaswamy Govindan
    Jingqin Luo
    A. Craig Lockhart
    Andrea Wang-Gillam
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 337 - 347
  • [49] A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors
    Park, Haeseong
    Williams, Kerry
    Trikalinos, Nikolaos A.
    Larson, Sarah
    Tan, Benjamin
    Waqar, Saiama
    Suresh, Rama
    Morgensztern, Daniel
    Van Tine, Brian A.
    Govindan, Ramaswamy
    Luo, Jingqin
    Lockhart, A. Craig
    Wang-Gillam, Andrea
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (03) : 337 - 347
  • [50] Phase I study of pemetrexed and sorafenib in advanced solid tumors.
    Poklepovic, Andrew Stewart
    Shafer, Danielle A.
    Roberts, John D.
    Geyer, Charles E.
    Dent, Paul
    Moran, Richard
    Tombes, Mary Beth
    Shrader, Ellen
    Strickler, Kathryn
    Wan, Wen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345